Zhanxue Xu
Overview
Explore the profile of Zhanxue Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Su D, Li M, Xie Y, Xu Z, Lv G, Jiu Y, et al.
J Control Release
. 2024 Nov;
377:127-145.
PMID: 39532207
Despite gut microbiota-derived extracellular vesicles (EVs) serving as pivotal mediators in bacteria-host cell interactions, their potential role in modulating skin inflammation remains poorly understood. Here, we developed strategies for mass...
2.
Lu X, Xu Z, Shu F, Wang Y, Han Y, Yang X, et al.
Adv Mater
. 2024 Jul;
36(35):e2406758.
PMID: 38949397
Heart transplantation offers life-saving treatment for patients with end-stage heart failure; however, ischemia-reperfusion injury (IRI) and subsequent immune responses remain significant challenges. Current therapies primarily target adaptive immunity, with limited...
3.
Yang X, Xu Z, Shu F, Xiao J, Zeng Y, Lu X, et al.
J Control Release
. 2024 Jun;
372:372-385.
PMID: 38901733
While surgical resection is the predominant clinical strategy in the treatment of melanoma, postoperative recurrence and undetectable metastasis are both pernicious drawbacks to this otherwise highly successful approach. Furthermore, the...
4.
Wang L, Liu X, Han Y, Tsai H, Dan Z, Yang P, et al.
Cancer Lett
. 2024 Apr;
590:216861.
PMID: 38583649
Immunotherapy represented by programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies has led tumor treatment into a new era. However, the low overall response rate and...
5.
Xu Z, Mao X, Lu X, Shi P, Ye J, Yang X, et al.
Adv Healthc Mater
. 2023 Nov;
13(7):e2302443.
PMID: 37962054
Although immunosuppressive drugs for targeting T cells are the standard of care in acute transplantation rejection, the role of innate immune cells should not be ignored. Here, single-cell RNA sequencing...
6.
Huang R, Jia B, Su D, Li M, Xu Z, He C, et al.
J Extracell Vesicles
. 2023 Oct;
12(10):e12361.
PMID: 37859568
Existing therapeutics for autoimmune diseases remain problematic due to low efficacy, severe side effects, and difficulties to reach target tissues. Herein, we design multifunctional fusion nanovesicles that can target lesions...
7.
Zhou Q, Yang Y, Xu Z, Deng K, Zhang Z, Hao J, et al.
EMBO Rep
. 2023 Oct;
24(11):e56614.
PMID: 37789674
ATPase family AAA domain-containing protein 1 (ATAD1) maintains mitochondrial homeostasis by removing mislocalized tail-anchored (TA) proteins from the mitochondrial outer membrane (MOM). Hepatitis C virus (HCV) infection induces mitochondrial fragmentation,...
8.
Xiao Y, Xu Z, Cheng Y, Huang R, Xie Y, Tsai H, et al.
Biomater Res
. 2023 Jun;
27(1):63.
PMID: 37391845
Background: Ferroptosis, iron-dependent cell death, is an established mechanism for cancer suppression, particularly in hepatocellular carcinoma (HCC). Sorafenib (SOR), a frontline drug for the treatment of HCC, induces ferroptosis by...
9.
Deng K, Zhou Q, Xu Z, Yang Y, Liu X, Li C, et al.
iScience
. 2023 Apr;
26(4):106421.
PMID: 37034976
Whether hypervariable region 1 (HVR1)-targeting antibodies elicited during natural hepatitis C virus (HCV) infection contribute to virus clearance and what is the mechanism underlying remain unclear. Here, we demonstrated that...
10.
Tsai H, Wu Y, Huang R, Su D, Wu Y, Liu X, et al.
Acta Pharm Sin B
. 2022 Jul;
12(4):1913-1927.
PMID: 35847518
Mutations in the plant homeodomain-like finger protein 6 () gene are strongly associated with acute myeloid (AML) and T-cell acute lymphoblastic leukemia (T-ALL). In this study, we demonstrated that PHF6...